TIMI 50

Principal Investigator:
William Felten, MD (Midland & MCVI)

Sub-Investigators:
Safwan Kassas, MD
Rao Gudipati, MD
Gregory Pellizzon, MD

Sponsor:
Schering-Plough Research Institute, a Division of Schering Corporation

Study Purpose:
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of SCH 530348 in Addition to Standard of Care in Subjects With a History of Atherosclerotic Disease: Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2°P - TIMI 50)

Objective:
To test the safety and effectiveness of SCH 530348, when used with standard medications that your doctor has decided you will receive for treatment of your atherosclerosis. SCH 530348 is given as a pill by mouth.

Status:
Active enrollment

If you have any questions, please feel free to contact the coordinators, and they will be happy to answer any questions you have regarding this study.

<< Back